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Background: Guidelines advise annual influenza vaccination in chronic asthma. The aim of this study was to
determine uptake of the influenza vaccine in a group of patients (n = 146) with moderate to severe chronic asthma
and establish the main predictors of vaccination.
Method: Patients attending a hospital asthma clinic were asked to complete a questionnaire in February 2012 (n = 146).
These same patients were contacted a year later via telephone (n = 109 responded), and they were asked to
complete the same questionnaire.
Results: Vaccination rate was 50.3% in winter 2011/12, and 57.8% in 2012/13. Using binary logistic regression, the
predictors for vaccination in 2012 were patient advice (Odds ratio [OR] 15.37 p = 0.001), female gender (OR 2.75,
p = 0.028), past side effects (OR 0.21, p = 0.001) and comorbidity (OR 0.39, p = 0.013). Stepwise regression resulted
in age as predictor (T value = 3.99, p = 0.001). On analyzing the responses from the second questionnaire at one
year after attendance to asthma clinic, predictors changed to compliance to medication (OR 9.52, p= 0.001) and
previous exacerbations (OR 4.19, p = 0.026). Out of the 56 patients vaccinated in 2011/12, 33 reported asthma
exacerbations before 2012, and 29 reported asthma exacerbations after receiving the influenza vaccine. Out of the
46 unvaccinated patients in 2012, 27 had asthma exacerbations before 2012 and 19 patients had exacerbations in
2013. Patients vaccinated in 2011/12 needed 0.59 courses of steroid/patient/year, and 1.23 visits for nebulizer/
patient/year while non-vaccinated patients needed 0.18 courses of steroids/patient/year (p = 0.048), and 0.65 visits
for nebulized/patient/year (p = 0.012). Patients’ subjective statements broadly confirmed the predictors. 16/69
(23.1%) received the vaccine in winter 2012/13 despite reporting previous side effects.
Conclusions: Advice to patient, female gender and patients’ age predicted vaccination, while past side effects to
the influenza vaccine, and presence of comorbidities predicted non vaccination. Symptomatic asthma patients are
more likely to be vaccinated. One year after the first contact, treatment compliance and previous asthma
exacerbations gained statistical significance as predictors of vaccination.
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Evidence shows that influenza vaccination leads to de-
creased hospitalization from influenza complications, fewer
deaths during the influenza season, decreased healthcare
costs in the elderly in the general population [1], and a de-
creased number of lost workdays and physician visits in
healthy adults [2]. Asthma patients are considered to be at
increased risk of influenza complications, however there is
conflicting evidence on the beneficial effect of influenza* Correspondence: rachasciak@gmail.com
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reproduction in any medium, provided the orvaccination on asthma exacerbations. Some studies suggest
that, at least in children, the vaccine decreases asthma ex-
acerbations [3], however in adults, a meta-analysis of pub-
lished studies has failed to demonstrate a significant
decrease in asthma exacerbations [4].
Despite this lack of evidence, the Global Initiative for
Asthma (GINA) guidelines issued in December 2011, ad-
vise that patients with moderate to severe asthma should
receive influenza vaccination every year or at least when
vaccination of the general population is advised. The
British Thoracic Society (BTS) guidelines on asthma
2008, revised in June 2009, also advise administration oftd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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related to asthma. The Advisory Committee on Immuni-
zation Practices (ACIP) recommends annual influenza
vaccination for adults and children with chronic disor-
ders of the pulmonary or cardiovascular systems, includ-
ing asthma.
This study was performed at Mater Dei Hospital, the
University hospital of Malta (population c. 411,277). At
this hospital the asthma clinics are run by Consultant Re-
spiratory physicians, who together with specialist trainees
in respiratory medicine and general medicine, see to pa-
tients attending these clinics. The clinics are run with the
help of a nurse. Many asthma patients are followed up in
the community, however most of the more severe cases
are referred to the asthma clinic for follow up.
The aim of this study was to determine the uptake of
the influenza vaccine in a group of patients with moderate
to severe chronic asthma and to try to establish the main
predictors of vaccination.Method
Between 17th January and 18th February 2012, adult pa-
tients with chronic asthma attending a hospital asthma
clinic were asked to fill in a standardized questionnaire,
with a Maltese and English version available according
to patients’ preference. Data collected included age, gen-
der, asthma control, whether patients had been advised
to receive the influenza vaccine or not, and if so by
whom. Questions included information on previous vac-
cination and side effects to the vaccine, whether the pa-
tient had received the vaccine this year or not, and the
reasons behind his/her decision. Patients were also asked
about comorbidities such as chronic kidney disease, for
which guidelines also advise influenza vaccination. Asthma
control was assessed by frequency of salbutamol use or
reliever medication, the need for systemic steroids or
nebulized treatment, and hospitalization over the past
12 months. After patients had filled in the question-
naire, participants received advice on the importance of
influenza vaccination in asthma patients.
The following year, in February 2013, the same patients
were contacted by telephone and the same questionnaire
was used, in order to follow up and compare results with
the previous year. At least two attempts were made to
contact each patient.
Patients were considered to have well-controlled asthma
if they rarely or never required their reliever salbutamol
inhaler, and did not need hospitalization, oral steroids or
nebulized treatment over the previous year. They were
considered to have poorly controlled asthma if they used
salbutamol several times daily and/or needed hospitaliza-
tion, oral steroids and nebulized treatment during the pre-
vious year.Compliance was assessed by asking patients how often
they forgot to take their medication. Those who never or
rarely forgot to take their asthma treatment were defined
as compliant, while patients who forgot to take their
treatment more than once a week or on a daily basis
were defined as being non-compliant. Patients with in-
complete questionnaires were excluded from the study.
Statistical analysis
The data collected was analyzed using Microsoft Office
Access® and Excel®. Categorical data was summarized
using percentages, and Fisher’s two-tailed exact test was
used for categorical values. Binary logistic regression
and Stepwise regression was determined using Minitab
16 software. P <0.05 was considered to be statistically
significant.
Consent
Authorization to perform this study was obtained from
the hospital’s data protection officer. Data protection
approval was deemed sufficient from an ethical point of
view. Consent was obtained from all the Consultant
Respiratory physicians in the hospital to interview
asthma patients under their care. Consent to perform
the questionnaires was obtained from all patients.
Results
A total of 146 patients (103 females, 43 males, mean age
47.9 years SD 19.3) suffering from chronic asthma were
studied. Out of these patients, 80 individuals (63 females
and 17 males) received the influenza vaccine during the
winter of 2011/12. This is a 50.3% vaccination rate after
correcting for gender.
109 patients (78 female, 31 male; mean age 53.6, SD 18.0)
responded to the second questionnaire the following year,
and vaccination rate rose to 57.8% (M 45.2%, F 70.5%)
after correcting for gender.
Table 1 shows the characteristics of the original 146
patients by gender. The mean age for those taking the
vaccine was 55.06 years, while the mean age for those not
taking the vaccine was 42.77 years (p = 0.0002). 86.2% of
the patients had been advised to take the vaccine. 62.4% of
the patients who were advised to take the vaccine were
vaccinated in winter 2011/12, while only 10% of those not
advised were vaccinated that winter (p = <0.0001).
In Table 2, binary logistic regression and stepwise re-
gression show patient advice and female gender as pre-
dictors for taking the vaccine, while comorbidity and a
history of previous side effects to the vaccine are shown
to be the main negative predictors for vaccination. Figure 1
shows the reasons asthma patients gave for taking the in-
fluenza vaccine that winter. Figure 2 shows the reasons
given by the patients for not taking the vaccine (patients
were given the option of choosing more than one reason).
Table 1 Characteristics of patients by gender in the
2011/12 questionnaire
Descriptor Male
(n= 43)
Female
(n= 103)
Averaged
rate
Mean age 47.95 50.41
Years of asthma 18.34 15.44
Life-time non-smokers 65.12% 79.61% 72.36%
Ex smoker 27.91% 16.50% 22.21%
Current smoker 6.98% 3.88% 5.43%
Reliever use
Never 41.86% 42.57% 42.22%
≤ twice weekly 6.98% 9.90% 8.44%
> twice weekly 4.65% 19.80% 12.23%
Once daily 16.28% 8.91% 12.59%
> once daily 30.23% 18.81% 24.52%
Compliant to preventer therapy 80.95% 73.74% 77.34%
Exacerbations previous year
Exacerbation occurrence 51.16% 59.22% 55.19%
Nebulizer therapy 34.88% 43.69% 39.29%
Oral steroid administration 32.56% 35.92% 34.24%
Hospitalization for asthma 13.95% 14.56% 14.26%
Intensive care admission 0.00% 2.91% 1.46%
Comorbidity 26.19% 30.30% 28.25%
Hypertension 23.26% 27.18% 25.22%
Diabetes 11.63% 10.68% 11.15%
Ischaemic heart disease 4.65% 2.91% 3.78%
Chronic kidney disease 2.33% 0.97% 1.65%
Table 2 Binary logistic regression and stepwise
regression of possible factors predicting vaccination for
influenza in 2011/12 (n=146)
Predictor (binary logistic regression) p Odds ratio 95% CI
Advised to take vaccine 0.001 15.37 2.98 79.13
Female gender 0.028 2.75 1.11 6.8
Compliance to medication 0.278 1.69 0.65 4.37
Exacerbations in previous year 0.294 1.61 0.66 3.9
Patient age 0.01 1.05 1.02 1.08
Asthma years 0.265 1.02 0.99 1.05
Frequency of reliever use 0.263 0.86 0.65 1.12
Comorbidity (0–4) 0.013 0.39 0.19 0.82
Previous side effects 0.001 0.21 0.08 0.53
Stepwise regression p T value
Advised to take vaccine 0.001 4.15
Previous side effects 0.001 −3.54
Patient age 0.001 3.99
Comorbidity (0–4) 0.021 −2.34
Female gender 0.021 2.34
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(84.4%) patients who responded to the questionnaire in
2013 reported previous vaccination, 78 (71.6%) had re-
ceived the vaccine at least once over the previous two
years, while 51 (46.8%) received the vaccine in both
years. 18 out of the 109 patients (17%) received the vac-
cine in winter 2012/13 but not in 2011/12. On the other
hand 9/109 patients did not revaccinate in 2012/13. Pre-
dictors of vaccination in 2012/13 using logistic and step-
wise regression are listed in Table 3 (102 patients with
complete data utilized).
According to the 51 patients who received the vaccine
in both years, the reasons for re-vaccination in 2012/13
were doctor’s advice (66.7%), to protect themselves (39.2%),
to protect family (13.7%), and to prevent asthma exacer-
bations (47.1%). The reasons given for vaccination in
2012/13 by patients who had not received the influenza
vaccine the previous year (n = 18) were physician advice
17 (93.5%,p = 0.002), to protect themselves - 5 (27.8%),
to protect family 1 (5.6%), and to prevent asthma exac-
erbations 4 (22.2%, p = 0.039).
31 patients (28.4%) did not receive the influenza vaccine
in either year. Out of these, 22 (71.0%) said this was be-
cause of fear of vaccine side effects. On the other hand,
there were 7 patients who had received the vaccine in win-
ter 2011/12, but not in 2012/13, and the reasons given
were fear of vaccine side effects (2), patients forgot to take
the vaccine (4), and patients did not feel the need to take
the vaccine (1).
13 out of 51 (25.5%) patients vaccinated in both years,
and 16 out of 69 (23.1%) patients vaccinated in 2012/13
had received the influenza vaccine in the second consecu-
tive year despite reporting previous side effects to the
vaccine.
Asthma reliever medication use amongst patients vac-
cinated in 2012/13, n = 69, (no information available on
two subjects), showed that 20 (29.0%) used short-acting
beta agonist daily or more frequently, 19 (27.5%) used it
2-6 times per week, and 30 (43.5%) never used it. For
non vaccinated patients in 2012/13 (n = 40) data was
17.5%, 22.5%, 60.0%, respectively (p = 0.22).
33 (58.9%) out of 56 patients vaccinated in 2011/12 re-
ported asthma exacerbations in the year preceding vaccin-
ation, and 29 reported exacerbations in the year following
vaccination, while out of 46 unvaccinated patients, 27 re-
ported exacerbations in the year prior to vaccination com-
pared to 19 in the following year.
Patients vaccinated in 2011/12 needed 0.59 courses of
systemic steroids/patient/year, and 1.23 visits for nebulizer/
patient/year in the following year. Non vaccinated patients
needed 0.18 courses of systemic steroids/patient/year
(p = 0.048), and 0.65 visits for nebulizer/patient/year
(p = 0.012) respectively. Unfortunately data prior to vac-
cination was not available.
Figure 1 Reasons asthma patients gave for taking influenza vaccine in winter 2011/12.
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This study showed that despite the recommendation for
influenza vaccination in asthma guidelines, just under
half of the patients with asthma failed to take the influ-
enza vaccine. The decision whether to take it or not is
influenced by several factors including trust or mistrust
in modern medicine, perceived side-effects from prior
vaccination, perceived risk associated with influenza [5],
and concern that vaccination may induce exacerbations
of asthma. A randomized controlled trial (RCT) involv-
ing 2,032 adults with asthma [6], and a large multicentre
cohort study [7] concluded that influenza vaccination in
asthma is safe.
In our study, the reported influenza vaccination rate of
57.8% was encouraging when compared to the 39.9% for
adult asthmatic patients in 2006-2007 in the USA [8],
and 40% vaccination rate in asthma patients in 2003 in a
single urban British general practice in Exeter [9].Figure 2 Reasons given by patients for not taking influenza vaccine iThis study was carried out on patients attending a hos-
pital asthma clinic; therefore patients were likely to suffer
from more severe asthma compared to patients treated in
primary care. In fact, 55.19% reported exacerbations in the
previous year, and 77.34% reported to be prescribed and
to be compliant with preventer medication.
The power of this study was insufficient to gauge the
impact of vaccination as there was an insignificant differ-
ence in exacerbation rates before and after vaccination for
individual vaccinated patients. However, there was a sig-
nificantly higher asthma exacerbation rate in vaccinated
patients when compared to unvaccinated patients. Though
not reaching statistical significance, non-vaccinated patients
seemed to use more short-acting reliever medication. This
could reflect the possibility that patients with more severe
symptoms are more likely to vaccinate against influenza.
On the contrary, it is also possible that those patients with
less severe or more intermittent asthma are less likely ton winter.
Table 3 Odds ratio for predictors of vaccination in 2012/13
(n = 102)
Binary logistic regression p Odds ratio 95% CI
Compliance to medication 0.001 9.52 2.42 37.5
Exacerbation in last year 0.018 4.8 1.31 17.6
Female gender 0.026 4.19 1.19 14.77
Advised to vaccinate 0.124 3.22 0.72 14.31
Frequency of reliever use 0.125 1.35 0.92 1.97
Age 0.017 1.05 1.01 1.09
Number of years asthma 0.232 0.98 0.94 1.02
Comorbidity (0–4) 0.575 0.66 0.16 2.81
Previous side effects 0.001 0.08 0.02 0.3
Stepwise regression p T Value
Compliance to medication 0.001 3.4
Previous side effects 0.001 −4.14
Exacerbation past year 0.011 2.6
Age 0.021 2.34
Female gender 0.022 2.33
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medication reflected a different behavioural attitude which
was not otherwise assessed in this study.
Unvaccinated patients reported a lower number of ex-
acerbations in the second year. This was probably the re-
sult of new attendants to the asthma clinic who besides
being offered vaccination could have their asthma better
controlled with medication. While this reason is specula-
tive, this explanation is supported by the emergence of
compliance to medication and the occurrence of previ-
ous exacerbations as a predictor for vaccination after
one year of attendance to the asthma clinic.
Using binary logistic regression in the first question-
naire, advice to the patient, and patient gender were the
best predictors of vaccination, while presence of comor-
bidities and having experienced previous vaccine side
effects were the negative predictors.
The effect of gender on vaccination rates in the general
population varies significantly between countries [10], and
in July 2010 a publication by the World Health Organization
in entitled ‘Sex, gender and influenza’ states that the severity
of asthma tends to be worse in women than in men, and
women are more likely than men to be caregivers. Because
of this, it is possible that women could be more aware of
influenza risk and the necessity to vaccinate themselves.
Other factors have been shown to affect influenza vaccin-
ation in asthma, including increased vaccination rates with
age [11]. In this study while the mean age of vaccinated
patients was higher than in non-vaccinated patients, logistic
regression failed to show it as a predictor, while stepwise
regression re-instated it. This may have occurred because
the stepwise regression model used only 5 statisticallysignificant predictors out of the 9 predictors evaluated, re-
moving the possible confounders of age. Logistic regression
had evaluated all the 9 predictors.
In the first questionnaire, receiving advice to vaccinate
heavily predicted influenza vaccination, but this effect
was greatly decreased in the second questionnaire as
probably many patients with a mindset not to vaccinate
had also received advice during the first questionnaire,
thus leveling off the difference between vaccinated and
non vaccinated individuals. However, one year after at-
tendance to the asthma clinic the second questionnaire
produced two new predictors, namely: compliance to
medication and occurrence of previous exacerbations.
This indicates that overall, patients at the asthma clinic
were not only advised to receive the influenza vaccine,
but their asthma treatment was also optimized.
18 patients who were vaccinated in 2012/13 and not in
2011/12 nearly unanimously stated that advice was crucial
in their decision making, especially doctors’ advice. Indeed
all patients on direct questioning highly rated the impact of
physician advice on their decision to vaccinate. Medical lit-
erature confirms that physician recommendations and edu-
cation about influenza vaccine availability, effectiveness, and
adverse effects [12] were other factors which were found to
influence parents to vaccinate their asthmatic children.
Both logistic regression and stepwise regression showed
that the most consistent negative predictor was the oc-
currence of past side effects to the influenza vaccine.
This was confirmed as the main reason for not vaccinat-
ing by the patients’ responses to direct questioning.
Notwithstanding this, a significant proportion of pa-
tients do actually vaccinate despite having experienced
previous vaccine side effects. This may reflect that side
effects are often minor when compared to the fear of
major attacks of acute asthma. This reason is supported
by the fact there was a greater likelihood for severely af-
fected patients to vaccinate.
Public Health vaccination campaigns tend to target
mainly the elderly population, who are more likely to
suffer from comorbidities. However in this study despite
the fact that 28% of patients had comorbidities, logistic
and stepwise regression gave a negative predictive value.
The study cannot offer an explanation for this result, ex-
cept that this may be a possible reason for an increased
fear of side effects of vaccination.
The main limitations of the study were that information
on whether the patient had been vaccinated or not during
the previous 12 months was obtained by self-report. The
statistical power was too low to give an indication of the
potential benefit of vaccination on the control of asthma
symptoms. Furthermore, the hospital environment might
have influenced respondents to praise the effect of med-
ical advice and perhaps overestimate their compliance to
medication.
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Advice by a medical practitioner or health care profes-
sional, female gender of patients, and increasing patient
age resulted in a higher vaccination rate. Fear of side-
effects and the presence of comorbidities were negative
predictors of vaccination. While this study could not as-
sess the effectiveness of the vaccine in preventing severe
attacks, patients with more severe symptoms are more
likely to vaccinate against influenza. One year after the
first questionnaire, compliance to medication and occur-
rence of a previous exacerbation became a positive pre-
dictor of vaccination. Around a fourth of patients with
asthma still vaccinate against influenza despite the previ-
ous occurrence of side effects.
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